STAT3 and osteosarcoma: Cisplatin is able to increase the expression of Nrf2 by activating STAT3 signaling, and the overactivation of STAT3/Nrf2 signaling mediates the enhancement of antioxidant capacity of cisplatin resistant osteosarcoma cells.